Compare AGMH & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGMH | ARTL |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 3.5M |
| IPO Year | 2017 | N/A |
| Metric | AGMH | ARTL |
|---|---|---|
| Price | $1.27 | $1.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 33.7K | 27.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $0.85 |
| 52 Week High | $18.10 | $28.60 |
| Indicator | AGMH | ARTL |
|---|---|---|
| Relative Strength Index (RSI) | 31.08 | 42.77 |
| Support Level | $0.06 | $1.10 |
| Resistance Level | $2.46 | $1.50 |
| Average True Range (ATR) | 0.09 | 0.13 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 7.69 | 33.33 |
AGM Group Holdings Inc is an integrated technology company. The company focuses on blockchain-oriented ASIC chip design, high-end crypto miner production, and fintech technology software services. The company generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.